Hualan Biological Vaccine Inc. Class A

Hualan Biological Vaccine Inc. Class A

SSZSE:301207
14.05
CNY
-0.25
(-1.75%)
0.08EPS
259.22P/E
12.09BMarket Cap
Mar 29Next Earn

Total Valuation

CNY

As of September 30, 2026, Hualan Biological Vaccine Inc. Class A carries a market capitalization of 12.09B, placing it among publicly traded companies globally. Its enterprise value stands at 9.99B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap12.09B
Enterprise Value9.99B

Important Dates

Hualan Biological Vaccine Inc. Class A's next confirmed earnings release is scheduled for March 29, 2027.

Earnings Date3/29/2027

Share Statistics

As of September 30, 2026, Hualan Biological Vaccine Inc. Class A has 601.03M shares outstanding.

Shares Outstanding601.03M

Valuation Ratios

As of September 30, 2026, Hualan Biological Vaccine Inc. Class A trades at a trailing price-to-earnings ratio of 259.22. The price-to-sales ratio is 17.16, and the price-to-book ratio stands at 2.34.

PE Ratio259.22
PS Ratio17.16
PB Ratio2.34
P/TBV Ratio2.36

Enterprise Valuation

As of September 30, 2026, Hualan Biological Vaccine Inc. Class A trades at an EV/EBITDA multiple of 309.50 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 14.33 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 309.50 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 9.99B versus a market cap of 12.09B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales14.33
EV / EBITDA309.50
EV / EBIT309.50

Financial Position

As of September 30, 2026, Hualan Biological Vaccine Inc. Class A maintains a current ratio of 4.63, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities.

Current Ratio4.63
Quick Ratio1.93

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Hualan Biological Vaccine Inc. Class A posted a return on equity (ROE) of 0.83, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 0.70, measuring how efficiently the asset base is converted into earnings. The company generates approximately 985,036.62 in revenue per employee across its workforce of 708.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.51 indicates how many times Hualan Biological Vaccine Inc. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)0.83
Return on Assets (ROA)0.70
Revenue Per Employee985,036.62
Employee Count708.00
Inventory Turnover0.51

Taxes

CNY

Over the twelve months ended September 30, 2026, Hualan Biological Vaccine Inc. Class A recorded an income tax benefit of -14.33M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 31.83M, leaving 46.16M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax-14.33M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Hualan Biological Vaccine Inc. Class A's stock has declined approximately 41.48% over the past 52 weeks. The 50-day moving average sits at 17.44, while the 200-day moving average is 18.51.

52-Week Price Change-41.48%
50-Day Moving Average17.44
200-Day Moving Average18.51

Income Statement

CNY

Over the twelve months ended September 30, 2026, Hualan Biological Vaccine Inc. Class A generated 697.41M in revenue and converted that into 46.16M in net income, yielding earnings per share of 0.08. EBITDA reached 32.29M, while operating income came in at 26.82M.

Revenue697.41M
Gross Profit503.52M
Operating Income26.82M
Pretax Income31.83M
Net Income46.16M
EBITDA32.29M
EBIT32.29M
Earnings Per Share (EPS)0.08

Balance Sheet

CNY

These figures are as of September 30, 2026. Total book value stands at 5.16B, with working capital of 3.95B providing operational flexibility.

Cash & Cash Equivalents2.09B
Net Debt-567.22M
Equity (Book Value)5.16B
Book Value Per Share8.59
Working Capital3.95B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-20.53M

Margins

Over the twelve months ended September 30, 2026, Hualan Biological Vaccine Inc. Class A posted a gross margin of 72.20, reflecting its pricing power and cost economics. The operating margin of 3.85 and net profit margin of 6.62 provide insight into operational efficiency.

Gross Margin72.20
Operating Margin3.85
Pretax Margin4.56
Profit Margin6.62
EBITDA Margin4.63

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Hualan Biological Vaccine Inc. Class A paid dividends of 0.69 per share. The dividend payout ratio of 890.38 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 6.98, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Hualan Biological Vaccine Inc. Class A shareholders.

Dividend Per Share0.69
Payout Ratio890.38
Shareholder Yield6.98

Stock Splits

Hualan Biological Vaccine Inc. Class A's most recent stock split took place on June 7, 2023 with a 2:3 split ratio.

Last Split Date6/7/2023
Split Ratio2:3

Scores

As of September 30, 2026, Hualan Biological Vaccine Inc. Class A has an Altman Z-Score of 7.77, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score7.77